Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab with Metformin As Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer

Next Previous
Search
Trial Profile

Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab with Metformin As Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Docetaxel; Metformin; Trastuzumab; Trastuzumab
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms met-HEReMYTA

    • Most Recent Events

    • 20 Apr 2020 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top